Sweetening Pharmaceutical Radiochemistry by 18F-Fluoroglycosylation: Recent Progress and Future Prospects

Shinde, Sandip S.; Maschauer, Simone; Prante, Olaf

doi:10.3390/ph14111175

Cited by 15 publications

(15 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These show excellent stability and clearance. These can be constructed to target a myriad of cell-specific features important in personalized medicine breast cancer and other malignancies [ 92 ].…”

Section: Breast Cancermentioning

confidence: 99%

PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies

Covington

Koppula

Fine

et al. 2022

Cancers

View full text Add to dashboard Cite

Positron emission tomography combined with x-ray computed tomography (PET-CT) is an advanced imaging modality with oncologic applications that include staging, therapy assessment, restaging, and surveillance. This six-part series of review articles provides practical information to providers and imaging professionals regarding the best use of PET-CT for the more common adult malignancies. The second article of this series addresses primary thoracic malignancy and breast cancer. For primary thoracic malignancy, the focus will be on lung cancer, malignant pleural mesothelioma, thymoma, and thymic carcinoma, with an emphasis on the use of FDG PET-CT. For breast cancer, the various histologic subtypes will be addressed, and will include 18F fluorodeoxyglucose (FDG), recently Food and Drug Administration (FDA)-approved 18F-fluoroestradiol (FES), and 18F sodium fluoride (NaF). The pitfalls and nuances of PET-CT in breast and primary thoracic malignancies and the imaging features that distinguish between subcategories of these tumors are addressed. This review will serve as a resource for the appropriate roles and limitations of PET-CT in the clinical management of patients with breast and primary thoracic malignancies for healthcare professionals caring for adult patients with these cancers. It also serves as a practical guide for imaging providers, including radiologists, nuclear medicine physicians, and their trainees.

show abstract

Section: Breast Cancermentioning

confidence: 99%

PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies

Covington

Koppula

Fine

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Positron emission tomography/computed tomography (PET/CT) imaging is currently used for the visualization of biological information of vulnerable plaque in clinical and pre-clinical cardiovascular research. The [ 18 F]FDG PET/CT has become a useful fusion technique for assessing large arterial inflammation noninvasively, and was proposed as a potential and feasible technique to assess plaque inflammation directly and to stratify patients by risk [8][9][10]. However, [ 18 F]FDG merely reflects glucose metabolism information and may lack specificity to discriminate infection, inflammation, and neoplastic disease [11].…”

Section: Introductionmentioning

confidence: 99%

Imaging Inflammation in Atherosclerosis with CXCR4-Directed [68Ga]PentixaFor PET/MRI—Compared with [18F]FDG PET/MRI

Xia

Calabretta

Wadsak

et al. 2022

Life

View full text Add to dashboard Cite

(1) This study compared [68Ga]PentixaFor uptake in active arterial segments with corresponding [18F]FDG arterial uptake as well as the relationship with cardiac [68Ga]PentixaFor uptake. (2) Method: Tracer uptake on atherosclerotic lesions in the large arteries was measured and target-to-background ratios (TBR) were calculated to adjust background signals with two investigators blinded to the other PET scan. On a patient-based and lesion-to-lesion analysis, TBR values of two tracers were compared and the relationship with cardiac inflammation was further explored. Furthermore, two cardiovascular risk-related groups were divided to explore the value of risk stratification of the two tracers in atherosclerosis. (3) Results: [68Ga]PentixaFor PET/MRI identified more lesions (88% vs. 48%; p < 0.001) and showed higher uptake than [18F]FDG PET/MRI (TBR, 1.90 ± 0.36 vs. 1.63 ± 0.29; p < 0.001). In the patient-based analysis, the TBR of [68Ga]PentixaFor uptake was also significantly higher than [18F]FDG uptake (1.85 ± 0.20 vs. 1.42 ± 0.19; p < 0.001). The TBR of active lesions for [68Ga]PentixaFor was significantly increased in the high-risk group (n = 9), as compared to the low-risk group (n = 10) (2.02 ± 0.15 vs. 1.86 ± 0.10, p = 0.015), but not for [18F]FDG (1.85 ± 0.10 vs. 1.80 ± 0.07, p = 0.149). (4) Conclusion: [68Ga]PentixaFor PET/MRI identified many more lesions than [18F]FDG PET/MRI. Patients with high-risk cardiovascular factors illustrated an increased uptake of [68Ga]PentixaFor. There was a correlation between the elevated uptake of [68Ga]PentixaFor in the active arterial segments and heart.

show abstract

“…Developments have led to sophisticated imaging techniques that can depict the functional properties of breast tumors and their underlying biology. Currently, 18 F-fluorodeoxyglucose positron emission tomography ( 18 F-FDG PET) as well as magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) techniques are the gold standard for the in vivo assessment of tumor metabolism ( 18 F-FDG PET), cellularity (DWI) and neoangiogenesis (DCE) [ 11 , 12 , 13 ]. For the assessment of TNBC in particular, both 18 F-FDG PET and MRI have shown high sensitivity [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

A Simultaneous Multiparametric 18F-FDG PET/MRI Radiomics Model for the Diagnosis of Triple Negative Breast Cancer

Romeo

Kapetas

Clauser

et al. 2022

Cancers

View full text Add to dashboard Cite

Purpose: To investigate whether a machine learning (ML)-based radiomics model applied to 18F-FDG PET/MRI is effective in molecular subtyping of breast cancer (BC) and specifically in discriminating triple negative (TN) from other molecular subtypes of BC. Methods: Eighty-six patients with 98 BC lesions (Luminal A = 10, Luminal B = 51, HER2+ = 12, TN = 25) were included and underwent simultaneous 18F-FDG PET/MRI of the breast. A 3D segmentation of BC lesion was performed on T2w, DCE, DWI and PET images. Quantitative diffusion and metabolic parameters were calculated and radiomics features extracted. Data were selected using the LASSO regression and used by a fine gaussian support vector machine (SVM) classifier with a 5-fold cross validation for identification of TNBC lesions. Results: Eight radiomics models were built based on different combinations of quantitative parameters and/or radiomic features. The best performance (AUROC 0.887, accuracy 82.8%, sensitivity 79.7%, specificity 86%, PPV 85.3%, NPV 80.8%) was found for the model combining first order, neighborhood gray level dependence matrix and size zone matrix-based radiomics features extracted from ADC and PET images. Conclusion: A ML-based radiomics model applied to 18F-FDG PET/MRI is able to non-invasively discriminate TNBC lesions from other BC molecular subtypes with high accuracy. In a future perspective, a “virtual biopsy” might be performed with radiomics signatures.

show abstract

Sweetening Pharmaceutical Radiochemistry by 18F-Fluoroglycosylation: Recent Progress and Future Prospects

Cited by 15 publications

References 87 publications

PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies

PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies

Imaging Inflammation in Atherosclerosis with CXCR4-Directed [68Ga]PentixaFor PET/MRI—Compared with [18F]FDG PET/MRI

A Simultaneous Multiparametric 18F-FDG PET/MRI Radiomics Model for the Diagnosis of Triple Negative Breast Cancer

Contact Info

Product

Resources

About